SunTrust Downgrades Abaxis (ABAX) to Neutral
More News related to ABAX
- Abaxis, Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
- Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
- Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2010
- Abaxis to Report Second Quarter Fiscal 2010 Financial Results Tuesday, October 27, 2009
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
More News related to Downgrades
- Broadcom Corp. (BRCM) to Acquire Dune Networks in $178M Transaction
- Forest Oil (FST) Agrees to Sell Remaining Permian Basin Assets to SandRidge (SD)
- Stericycle (SRCL) Gets Clearance to Buy MedServe; Companies Agree to Reduce Merger Consideration to $182.5M
- Playboy (PLA) May Sell TV/Online Business to Cisneros or FriendFinder; Sale Moving Faster Than Expected
- NYSE Euronext (NYX) Completes Purchase of NYFIX (NYFX)
SunTrust downgrades Abaxis (Nasdaq: ABAX) from Buy to Neutral.
To see more analyst ratings on ABAX Click Here.
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets worldwide.
Related Categories
DowngradesStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
